title: Biological Character of RetroNectin Activated Cytokine-Induced Killer Cells.
abstract: Adoptive cell therapy (ACT) using autologous cytokine-induced killer (CIK) cells is a promising treatment for metastatic carcinomas. In this study, we investigated the impact of RetroNectin on the proliferation, phenotype alternation, cytokine secretion, and cytotoxic activity of CIK cells from pancreatic cancer patients. Furthermore, we treated 13 patients with metastatic or locally advanced pancreatic cancer using autologous RetroNectin-activated CIK cells (R-CIK cells) alone or in combination with chemotherapy. Compared with only CD3 activated CIK cells (OKT-CIK cells), R-CIK cells showed stronger and faster proliferative ability, with a lower ratio of spontaneous apoptosis. Moreover, this ability continued after IL-2 was withdrawn from the culture system. R-CIK cells could also secrete higher levels of IL-2 and lower levels of IL-4 and IL-5 versus OKT-CIK cells. There was no difference between OKT-CIK and R-CIK cells in cytotoxic ability against lymphoma cell line K562. In patients who received auto-R-CIK cell infusion therapy, the overall objective response rate was 23.1%. Median survival time (mOS) after first R-CIK cell infusion was 10.57 months; the 1-year survival rate was 38.5%. No serious toxicity was associated with R-CIK cell infusion. In conclusion, RetroNectin may enhance antitumor activity of CIK cells: it is safe for use in treating pancreatic cancer.
authors.affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
authors.forename: Lu
authors.identifier: 0000-0002-9004-4458
authors.initials: L
authors.lastname: Han
authors.affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
authors.forename: Yi-Man
authors.identifier: 0000-0001-6849-4121
authors.initials: YM
authors.lastname: Shang
authors.affiliation: Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
authors.forename: Yong-Ping
authors.identifier: 0000-0002-8785-0029
authors.initials: YP
authors.lastname: Song
authors.affiliation: Department of Immunology, Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou, Henan 450008, China.
authors.forename: Quan-Li
authors.identifier: 0000-0002-9947-8818
authors.initials: QL
authors.lastname: Gao
mesh_terms: D000368:Aged; D017209:Apoptosis; D055612:Cytokine-Induced Killer Cells / Q000187:drug effects* / Q000276:immunology* / Q000502:physiology; D016207:Cytokines / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D005260:Female; D005353:Fibronectins / Q000494:pharmacology*; D006801:Humans; D016130:Immunophenotyping; D016219:Immunotherapy, Adoptive / Q000009:adverse effects*; D007376:Interleukin-2 / Q000494:pharmacology; D020014:K562 Cells; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000628:therapy*; D011994:Recombinant Proteins / Q000494:pharmacology*; D015996:Survival Rate
chemical_list: D016207:Cytokines; D005353:Fibronectins; D007376:Interleukin-2; D011994:Recombinant Proteins; C545354:retronectin